SAN Stock Overview
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
No risks detected for SAN from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||€84.75|
|52 Week High||€106.66|
|52 Week Low||€76.45|
|1 Month Change||-15.30%|
|3 Month Change||-15.07%|
|1 Year Change||-2.95%|
|3 Year Change||13.26%|
|5 Year Change||2.41%|
|Change since IPO||103.73%|
Recent News & Updates
|SAN||FR Pharmaceuticals||FR Market|
Return vs Industry: SAN underperformed the French Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: SAN exceeded the French Market which returned -6.3% over the past year.
|SAN Average Weekly Movement||3.9%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.0%|
|10% most volatile stocks in FR Market||9.0%|
|10% least volatile stocks in FR Market||2.8%|
Stable Share Price: SAN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SAN's weekly volatility (4%) has been stable over the past year.
About the Company
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Sanofi Fundamentals Summary
|SAN fundamental statistics|
Is SAN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SAN income statement (TTM)|
|Cost of Revenue||€12.84b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 28, 2022
|Earnings per share (EPS)||5.31|
|Net Profit Margin||15.80%|
How did SAN perform over the long term?See historical performance and comparison
3.9%Current Dividend Yield
Is SAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SAN?
Other financial metrics that can be useful for relative valuation.
|What is SAN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SAN's PE Ratio compare to its peers?
|SAN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the peer average (22.6x).
Price to Earnings Ratio vs Industry
How does SAN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the French Pharmaceuticals industry average (23.3x)
Price to Earnings Ratio vs Fair Ratio
What is SAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||16x|
|Fair PE Ratio||29x|
Price-To-Earnings vs Fair Ratio: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the estimated Fair Price-To-Earnings Ratio (29x).
Share Price vs Fair Value
What is the Fair Price of SAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SAN (€84.75) is trading below our estimate of fair value (€237.45)
Significantly Below Fair Value: SAN is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Sanofi forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAN's forecast earnings growth (9.5% per year) is above the savings rate (0.3%).
Earnings vs Market: SAN's earnings (9.5% per year) are forecast to grow slower than the French market (11.5% per year).
High Growth Earnings: SAN's earnings are forecast to grow, but not significantly.
Revenue vs Market: SAN's revenue (4.3% per year) is forecast to grow slower than the French market (5.2% per year).
High Growth Revenue: SAN's revenue (4.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SAN's Return on Equity is forecast to be low in 3 years time (14%).
Discover growth companies
How has Sanofi performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAN has high quality earnings.
Growing Profit Margin: SAN's current net profit margins (15.8%) are higher than last year (15.4%).
Past Earnings Growth Analysis
Earnings Trend: SAN's earnings have grown by 17.5% per year over the past 5 years.
Accelerating Growth: SAN's earnings growth over the past year (15%) is below its 5-year average (17.5% per year).
Earnings vs Industry: SAN earnings growth over the past year (15%) underperformed the Pharmaceuticals industry 15%.
Return on Equity
High ROE: SAN's Return on Equity (9.4%) is considered low.
Discover strong past performing companies
How is Sanofi's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SAN's short term assets (€28.6B) exceed its short term liabilities (€22.1B).
Long Term Liabilities: SAN's short term assets (€28.6B) exceed its long term liabilities (€28.4B).
Debt to Equity History and Analysis
Debt Level: SAN's net debt to equity ratio (17%) is considered satisfactory.
Reducing Debt: SAN's debt to equity ratio has reduced from 31.8% to 26.7% over the past 5 years.
Debt Coverage: SAN's debt is well covered by operating cash flow (50.6%).
Interest Coverage: SAN's interest payments on its debt are well covered by EBIT (28.2x coverage).
Discover healthy companies
What is Sanofi current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SAN's dividend (3.93%) is higher than the bottom 25% of dividend payers in the French market (1.67%).
High Dividend: SAN's dividend (3.93%) is low compared to the top 25% of dividend payers in the French market (5.26%).
Stability and Growth of Payments
Stable Dividend: SAN's dividends per share have been stable in the past 10 years.
Growing Dividend: SAN's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (62.8%), SAN's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (54.9%), SAN's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Hudson (55 yo)
Mr. Paul Hudson has been Chief Executive Officer and Director at Sanofi since September 1, 2019. Mr. Hudson was Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016 until J...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD11.34M) is above average for companies of similar size in the French market ($USD3.99M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Management: SAN's management team is seasoned and experienced (7.1 years average tenure).
Experienced Board: SAN's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sanofi's employee growth, exchange listings and data sources
- Name: Sanofi
- Ticker: SAN
- Exchange: ENXTPA
- Founded: 1973
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €106.107b
- Shares outstanding: 1.25b
- Website: https://www.sanofi.com
Number of Employees
- 54, Rue La BoEtie
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/11 00:00|
|End of Day Share Price||2022/08/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.